Kornimate/medical-research-clean huggingface dataset:
postoperative analgesic efficacy of pericapsular nerve group block (peng) block for knee arthroscopy

Conditions: Postoperative Pain

Summary: pericapsular nerve group block (peng) has been deemed as a safe and effective regional technique for postoperative pain after knee arthroscopy.

pericapsular nerve group block(peng) has been deemed as a safe and effective regional technique for postoperative pain after knee artroscopy. blockade of the branches of the femoral and obturator nerves that provide innervation to any structures distal enough to be useful in knee.

Eligibility criteria:
inclusion criteria: * patients agreed to receive peng block * knee arthroscopy exclusion criteria: * other kinds of knee surgery * patients refuse to receive peng block
right ventricular dysfunction incidence after major lung resection

Conditions: Major Lung Resection; Right Ventricular Dysfunction

Summary: this study aims to describe incidence of right ventricular dysfunction after major lung resection with echocardiography criteria.

few clinical trial studied the incidence of right ventricular dysfunction after major lung resection and time frame of occurrence. in this prospective observational study the right ventricular function will be mesure with echocardiographic criteria. echocardiographic exam will be standardised and be realised day before surgery (at the same time that inclusion), day 1, day 2 and day 3 after surgery. in order to assess prognostic value of right dysfunction after lung resection, data as hospitalization stay, complications and survival will be collected at 6 months. cardiac cycles will be recorded and be analysed by a single observer blind to the clinical finding and other echocardiographic measurements.

Eligibility criteria:
inclusion criteria: * written consent * patient older than 18 years * major lung surgery (pneumonectomy, lobectomy) exclusion criteria: * pre-existing pulmonary arteria hypertension * post-operative surgical complication on day 1 to 3 (bleeding, revision surgery) * technical difficulty preventing adequate echocardiographic assessment * patient refusal

Keywords: major lung resection right ventricular dysfunction 2d strain
a prospective, multi-center evaluation of a powered vascular stapler in video-assisted thoracoscopic lobectomies

Conditions: Non-Small Cell Lung Cancer

Summary: the primary objective of this trial is to demonstrate the effectiveness of the powered vascular stapler for transection of the pulmonary artery (pa) and pulmonary vein (pv) during video-assisted thoracoscopic lobectomy.


Eligibility criteria:
inclusion criteria: 1. subjects with a confirmed or suspected diagnosis of stage ia to stage iib non-small cell lung cancer scheduled for lobectomy (lung cancer staging per american joint committee on cancer,7th edition)7; 2. subjects scheduled for vats lobectomy in accordance with their institution's soc; 3. performance status 0-1 (eastern cooperative oncology group classification); 4. asa score \< 3; 5. no prior history of vats or open lung surgery (on the lung in which the procedure will be performed); 6. willing to give consent and comply with study-related evaluation and treatment schedule; and 7. 18-75 years of age (inclusive). exclusion criteria: 1. active (subject currently receiving systemic treatment) bacterial infection or fungal infection; 2. systemic administration (intravenous or oral) of steroids, including herbal supplements that contain steroids (within 30 days prior to study procedure); 3. uncontrolled diabetes mellitus; 4. end stage renal or liver disease; 5. history of severe cardiovascular disease; 6. fev1% \<50% or severe copd; 7. prior chemotherapy or radiation for lung cancer; 8. scheduled concurrent surgical procedure other than diagnostic wedge resection followed by lobectomy (central venous access - e.g., port placement, mediastinoscopy with lymph node sampling, and vats lymphadenectomy are allowed); 9. robotic-assisted procedure; 10. women who are pregnant or lactating at the time of screening; 11. physical or psychological condition which would impair study participation; 12. the subject is judged unsuitable for study participation by the investigator for any other reason; 13. participation in any other investigational drug (within 30 days or 5 half-lives of an investigational drug) or device study; or 14. unable or unwilling to attend follow-up visits and examinations.
patient perception questionnaire validation

Conditions: Obstructive Sleep Apnea

Summary: validation of the patient perception questionnaire relating to cpap use

this research is designed to validate a questionnaire which aims to predict patient adherence to cpap, therefore enabling the healthcare provider to better target initiatives to improve adherence.

Eligibility criteria:
inclusion criteria: * mild-severe osa patients * over 18 * naive to cpap * fluent english exclusion criteria: * comorbidities * other sleep disorders * inability to tolerate cpap * shift worker
long-term characterization of patients with severe/critical infection by covid-19 virus

Conditions: Covid19

Summary: a descriptive study to characterize clinical, radiological, lung function and quality of life alterations in patients who survived a severe or critical disease caused by sars-cov-2 virus, who were treated in the intensive care unit of a high complexity institution in cali, colombia.


Eligibility criteria:
inclusion criteria: * ≥ 19 years old who had a positive test for sars-cov-2 virus * patients with a severe and critical disease by sars-cov-2, who were treated at the icu of fundación valle del lili, and survived * patients with chest radiography or ct scan at admission to the hospital exclusion criteria: * patients who do not sign informed consent.

Keywords: covid19 lung function quality of life
boron neutron capture therapy in treating patients with melanoma

Conditions: Melanoma (Skin)

Summary: rationale: boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. purpose: phase ii trial to study the effectiveness of boron neutron capture therapy in treating patients who have melanoma.

objectives: * determine the clinical response, by serial objective measurements, in patients with melanoma treated with boron neutron capture therapy. * determine the time course, uniformity, and severity of acute dermal reactions in patients treated with this regimen. * determine the late dermal reactions in patients who are followed for at least 6 months after treatment with this regimen. * determine the pharmacokinetics of this regimen in these patients. outline: patients are stratified according to tumor size (no greater than 15 cc vs greater than 15 cc). patients undergo boron neutron capture therapy. patients are followed for 3 years. projected accrual: a total of 36 patients will be accrued for this study within 3 years.

Eligibility criteria:
disease characteristics: * histologically confirmed melanoma * evaluable disease * lesion(s) to be irradiated must be located in 1 of the following areas: * on an extremity * on the head or neck (including the scalp) * in the subdermal lymphatics (excluding the proximal axilla) * area to be irradiated must not exceed a maximum dimension of 10 cm * maximum tumor depth from the surface of the skin cannot exceed 6 cm patient characteristics: age * 18 and over performance status * ecog 0-1 life expectancy * more than 6 months hematopoietic * not specified hepatic * not specified renal * creatinine normal cardiovascular * no history of severe cardiac disease * no uncontrolled arrhythmias or conduction defects * no unstable or newly diagnosed angina pectoris * no recent coronary artery disease * no congestive heart failure other * not pregnant * negative pregnancy test * no history of phenylketonuria * must have sufficient mental competence prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * no prior radiotherapy to study sites surgery * not specified

Keywords: recurrent melanoma stage 0 melanoma stage i melanoma stage ii melanoma stage iii melanoma stage iv melanoma
effect of cyanobacteria patients with chronic hepatitis b surface antigen quantitative concentration

Conditions: HBV Carrier

Summary: hepatocellular carcinoma (hcc) is a very severe disease in taiwan caused 7,000 deaths per year, and majorly about 70% is caused by the chronic hepatitis b virus infection. a repeat, long-term, and severe chronic hepatitis would be more possible progressed into liver cirrhosis and hcc. as previous records, there might be 2% of chronic hbv patient would progress to liver cirrhosis, and 5% of the liver cirrhosis's patients would develop to hcc. in some cases, the hbv patient also might directly develop to hcc without liver cirrhosis phase.

hepatocellular carcinoma (hcc) is a very severe disease in taiwan caused 7,000 deaths per year, and majorly about 70% is caused by the chronic hepatitis b virus infection. a repeat, long-term, and severe chronic hepatitis would be more possible progressed into liver cirrhosis and hcc. as previous records, there might be 2% of chronic hbv patient would progress to liver cirrhosis, and 5% of the liver cirrhosis's patients would develop to hcc. in some cases, the hbv patient also might directly develop to hcc without liver cirrhosis phase. spirulina platensis is a kind of ancient livings for a 3.5 billions years, and had been recognized as a kind of space food by national aeronautics and space administration(usa) because of containing numerous nutrients, especially vitamin b and beta-carotene. beta-carotene would convert into vitamin a and help keep health vision, skin, and mucosa. with a rich source of vitamins b, especial b12 which is almost only in meals (animal livers), 1.2 grams of spirulina platensis daily uptake would be sufficient for a human daily need, and also be a very good source for vegetarians. the investigators add the b12 test in this trial as a secondary endpoint to help monitor the absorption rates of the spirulina platensis in human. otherwise, the plant pigments in spirulina platensis would also have many bioactivities on human healthy. among these bio-activities of spirulina platensis would contain anti-virus, anti-cancer, immune modulation, anti-inflammation, anti-oxidant, improve liver abnormality, and liver cirrhosis abilities. as previous small scale of clinical trial results in hbv patients provided by far east bio-tec company, lamivudine combined with oral spirulina platensis would also improve the sero-conversion rates of hbeag.

Eligibility criteria:
inclusion criteria: * in patients with chronic hepatitis b of taking oral antiviral drugs , and the virus has been detected is less than the amount (hbv dna \<20 iu / ml), aged between 20 years to 75 years . exclusion criteria: * patients were allergic to seafood.
low dose hcg in the late follicular phase

Conditions: Infertility

Summary: in this study,the investigators compared two protocols for controlled ovarian hyperstimulation in infertility patients requiring ivf. in the control group, the patient undergoes a standard antagonist protocol. in the study group, the administration of gonadotropins is stopped in the late follicular phase and replaced by low dose human chorionic gonadotropins. the primary endpoint of the study is the number of oocytes retrieved in both groups.


Eligibility criteria:
inclusion criteria: * \< 36 years on day of randomisation * fsh \< 12 in the early follicular phase * normal ultrasound scan * bmi between 18 and 29 (both inclusive) * randomisation at outpatient clinic exclusion criteria: * endometriosis ≥ grade 3 * pco syndrome * poor responder * endocrine or metabolic abnormalities

Keywords: infertility ivf hcg primary infertility secondary infertility patients requiring in-vitro fertilisation
study of laser interstitial thermal therapy (litt) treatment response assessment with fluciclovine pet mr

Conditions: Brain Metastases; Cancer; Gliomas; Glioblastoma

Summary: the purpose of this study is to assess the relationship between brain malignancy volume as defined by post-contrast t1 weighted and f18 fluciclovine before and following litt. we hypothesize that imaging with f18 fluciclovine will be superior to anatomic mr imaging in lesion volume assessment before treatment and that residual f18 fluciclovine defined tumor will predict local post-litt disease recurrence.

primary objectives -to estimate the accuracy of f18 fluciclovine pet mr for laser interstitial thermal therapy (litt) treatment response assessment as determined by t1 post-contrast mr brain imaging. secondary objectives * to assess changes in f18 fluciclovine defined disease with litt. * to assess the volume change of the idealized quantitative t1 values of lesions compared -to assess the volume change of idealized quantitative t2 values of lesions compared to -chemical exchange saturation transfer (cest) mri - to assess the ability of cest imaging to differentiate treatment change from residual disease in brain malignancy following litt. * multiple b value diffusion imaging (adv diff) - to assess whether adv diff can differentiate treatment changes from residual disease in brain malignancy following litt. * gradient- and spin-echo dsc perfusion imaging - to assess whether gese dsc improves differentiation of treatment change from residual disease in brain malignancy -adv asl perfusion imaging - to assess the ability of adv asl to differentiate treatment change from residual disease in brain malignancy following radiation therapy. * exploratory objectives * to assess the relationship between post-litt enhancing brain tissue and f18 -to assess changes in regional homogeneity (reho) values after litt.

Eligibility criteria:
inclusion criteria * an adult patient with suspected or pathology-proven central nervous system neoplasm. * mri of the brain, positive for at least one intra-axial lesion greater than 5 mm. exclusion criteria * contraindication to mr imaging. * known allergy to gadolinium-based contrast agents. * renal failure as defined by a gfr less than 30 or the use of hemodialysis. * pregnant. * patients less than 18 years of age will be excluded.
to compare the strategies of universal antibiotic prophylaxis versus screen-and-treat in reducing infective complications and re-infection in women who undergo termination of pregnancy

Conditions: Induced Abortion; Postaboral Pelvic Inflammatory Disease; Sexually Transmitted Infections

Summary: screen-and-treat approach reduces postabortal pelvic inflammatory disease after induced abortion, and at the same time alters women's sexual behavior and prevents further re-infection by sexually transmitted infections when compared to the universal antibiotic prophylaxis strategy.

while universal antibiotic prophylaxis during induced abortion has been proven to reduce postabortal pelvic inflammatory diseases, screen-and-treat approach has the potential benefit of altering women's sexual behavior and preventing further re-infection by sexually transmitted infections. we conducted a randomized controlled trial to compare the effect of the two approaches in preventing postabortal pelvic inflammatory disease and the women's sexual behavior.

Eligibility criteria:
inclusion criteria: * women requesting for induced abortion in the gynecology clinic exclusion criteria: * nil

Keywords: induced abortion postaboral pelvic inflammatory disease sexually transmitted infections universal antibiotic prophylaxis screen-and-treat approach
vildagliptin and the glucagon response to hypoglycemia in insulin-treated patients with type 2 diabetes

Conditions: Diabetes

Summary: the purpose of this study is to explore whether the novel therapy of type 2 diabetes, vildagliptin, which inhibits dipeptidyl peptidase-4 (dpp-4), affects glucagon counterregulation during hypoglycemia in insulin-treated patients with type 2 diabetes. vildagliptin is given, together with the on-going insulin therapy, for one month, whereafter hypoglycemia is induced under standardized conditions, and the glucagon response is determined, and compared to that after a month of placebo treatment.

vildagliptin is an inhibitor of dipeptidyl peptidase-4 (dpp-4) and inhibits glucagon secretion and stimulates insulin secretion. this improves glycemia in subjects with type 2 diabetes with a very low risk for hypoglycemia. if hypoglycemia nevertheless develops, it is important that vildagliptin under such conditions does not inhibit glucagon secretion, since that would aggravate the hypoglycemia. it was indeed previously demonstrated in type 2 diabetes that vildagliptin dos not inhibit glucagon secretion during hypoglycemia. this study explores whether vildagliptin affects glucagon counterregulation during hypoglycemia in insulin-treated patients of type 2 diabetes. vildagliptin is given, together with the on-going insulin therapy, for one month, whereafter hypoglycemia is induced under standardized conditions, and the glucagon response is determined, and compared to that after a month of placebo treatment. the hypoglycemia is induced bvy a standardized clamp procedure.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * insulin treatment * age \>18 years * hba1c \<=8.5% exclusion criteria: * pregnancy * lactation * acute infection * liver disease * treatment with cortisol

Keywords: dpp-4 glp-1 glucagon catecholamines counterregulation insulin-treatment type 2 diabetes
lifestyle program for obstructive sleep apnea with severe obesity

Conditions: Obstructive Sleep Apnea; Obesity

Summary: the purpose of this study is to develop a data driven system for persons with severe obesity sleep apnea that utilizes remote monitoring with health coaching to create behavior changes aimed at improving health and quality of life.


Eligibility criteria:
inclusion criteria: * adult patients, 18 years of age or older. * newly diagnosed with severe obstructive sleep apnea (osa) and severe obesity (bmi \> 35). exclusion criteria: * individuals \< 18 years of age. * patients with an inability to provide good data or follow commands (patients who are disoriented, have a severe neurologic or psychiatric condition).
fetal pulmonary artery acceleration to ejection time ratio (patet) in the prediction of subsequent development of respiratory distress syndrome (rds)

Conditions: RDS

Summary: fetal patet ratio evaluation to predict neonatal rds

115 patients were enrolled in this study.population was recruited from singleton pregnancies beyond 27 weeks of gestation.all participants underwent a ultrasound examination to measure fetal pulmonary artery acceleration to ejection time ratio (patet) by a single experienced clinician. after the delivery respiratory distress diagnosis made by a pediatrician who were blinded the doppler waveform measurements.following the diagnosis, neonates divided into 2 groups as rds (+) and rds (-). in addition of rds diagnosis, neonatal features like 1st and 5th minute apgar scores, neonatal intensive care unit (nicu) admission and duration in nicu were also recorded. afterwards all parameters were statistically analyzed if there is any significant differences between those two groups.

Eligibility criteria:
inclusion criteria: * pregnant women within the 27 weeks of gestation and beyond exclusion criteria: * patients who did not give birth within 3 days after the ultrasonographic doppler examination * fetuses with any congenital abnormalities * amniotic fluid abnormalities * any chronic maternal diseases or pregnancy complications such as;gestational diabetes mellitus,preeclampsia
a randomized clinical trial for toddlers with asd

Conditions: Autism Spectrum Disorder

Summary: this research is being done to test the effectiveness of two treatments aimed at increasing language and social skills in children with autism spectrum disorder. if children show improvement in these treatments, we hope that the availability of public services for minority and low income families will be increased. minority and low income families with children between 22 and 33 months of age with autism spectrum disorders may join.


Eligibility criteria:
inclusion criteria: * participants must be 22 to 33 months old * children must meet criteria for asd or autism on the ados plus receive a clinical judgment of pdd-nos or autism by the study team * children must have an age equivalent of 8 months or greater for non-verbal ability based on the mullen visual reception and fine motor scales * parents must agree to participate in the study and commit to having their child participate in the intervention to which they are randomized for 6 months * the parent (or other primary caregiver, such as grandparent) in the parent-mediated condition must agree to attend the training sessions three times per month * parents must be between the ages of 16 and 50 years old * families who qualify for medical assistance and/or have racial/ethnic minority backgrounds will be prioritized for recruitment and participation in this study. on the tsi, we will ask participants if they qualify for medical assistance or if they are of a racial minority or have a first degree relative of a racial minority. families who do not fit these criteria will be notified that they may be eligible to participate if additional space is available. * it is not required that english be their primary language, but they must be fluent in english (or if the child is nonverbal he/she must hear english most of the time at home) exclusion criteria: * head injury prior to enrollment in the study * major hearing or visual impairment after correction * non-febrile seizures * pku (phenylketonuria) * congenital rubella (german measles) * neurofibromatosis * tuberous sclerosis * fragile x * a fall resulting in a loss of consciousness or other severe head injury * velo-cardio facial syndrome * any other known genetic syndrome * no foster children may participate * the child must not be adopted

Keywords: autism spectrum disorder language social toddlers
long-term safety of bimatoprost ophthalmic solution in patients with glaucoma or ocular hypertension

Conditions: Glaucoma; Ocular Hypertension

Summary: this study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * ocular hypertension or glaucoma in each eye * requires intraocular pressure (iop)-lowering therapy in both eyes * best corrected visual acuity of 20/100 or better in each eye exclusion criteria: * ocular seasonal allergies within 2 years * required chronic use of ocular medications during the study (intermittent use of artificial tears is allowed) * ocular surgery or laser within 3 months * anticipated wearing of contact lenses during the study
kino-dyspnea: validation of kinocardiography to distinguish dyspnea of cardiac origin from others

Conditions: Dyspnea

Summary: seismocardiography (scg) measures the thoracic vibrations caused by the cardiac contraction and ejection of blood into the great vessels. current smartphones with gyroscopes and accelerometers can measure these vibrations. based on these components we measure and quantify the cardiac kinetic energy (kinocardiography) in order to differentiate dyspnea of cardiac origin from dyspnea of other origin. the study is conducted in an emergency service where a smartphone performs the measurement during 3 minutes. the results of the kinocardiography-based classification are then compared to the final diagnosis made by a physician. currently, 235 patients have been included in the clinical study since may 2022. this rapid and non-invasive measurement allows the aid-to-diagnosis of heart failure without being influenced by other factors like the renal function for example that can be nt-pro bnp blood marker.


Eligibility criteria:
inclusion criteria: * dyspnea. * adults aged above 18 years old. exclusion criteria: * patients younger than 18 years old.